Condition

Diffuse Large B Cell Lymphoma clinical trials and research

• 105Clinical trials
• 1New in 30 days
• 52Countries

Newest Diffuse Large B Cell Lymphoma clinical trials

All recruiting trials (105)

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Glofitamab combo vs Rituximab combo with chemo for relapsed/refractory DLBCL

  This study tests whether glofitamab with chemotherapy (JS203-GemOx) helps patients with relapsed or refractory DLBCL more than rituximab with chemotherapy.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT07808827

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• External beam radiation followed by bispecific antibody therapy for relapsed or refractory DLBCL

  This study tests whether giving targeted radiation first, then bispecific antibodies (epcoritamab or glofitamab), is tolerable for adults with relapsed or refractory diffuse large B-cell lymphoma.

  Recruiting Phase 1 University of Utah · Salt Lake City, Utah · NCT07528352

• Chidamide maintenance for MRD-positive double-expressor DLBCL in first remission

  This study tests whether giving chidamide as maintenance therapy can help people with double-expressor DLBCL who have complete remission but still have MRD detected in their blood.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07507318

• Cognitive changes in people treated for diffuse large B‑cell lymphoma

  This study tests whether adults with newly diagnosed diffuse large B‑cell lymphoma experience cognitive changes during and after standard chemotherapy.

  Recruiting Institute of Oncology Ljubljana · Ljubljana · NCT07443514

• Anti‑PD1 armored CD19 CAR‑T therapy for relapsed or refractory diffuse large B‑cell lymphoma

  This trial will test whether anti‑PD1 armored CD19 CAR‑T cell therapy is safe and tolerable in adults with relapsed or refractory diffuse large B‑cell lymphoma.

  Recruiting Phase 1 Jiangsu Topcel-KH Pharmaceutical Co., Ltd. · Suzhou · NCT07368270

• Axicabtagene ciloleucel for adults with late-relapsing diffuse large B‑cell lymphoma

  This trial will try axicabtagene ciloleucel (a CD19 CAR‑T cell therapy) in adults with diffuse large B‑cell lymphoma who have a late relapse after initial treatment.

  Recruiting at 15 sites Phase 2 Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · A Coruña, A Coruña and 14 other locations · NCT07254754

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Glofitamab for Chinese adults with second-line relapsed or refractory diffuse large B‑cell lymphoma

  This will test whether glofitamab-based therapy helps and is safe for Chinese adults whose diffuse large B‑cell lymphoma returned or didn't respond after one prior treatment.

  Recruiting at 22 sites Hoffmann-La Roche · Langfang, Hebei and 21 other locations · NCT07200375

• Drug-eluting bead transarterial chemoembolization for large recurrent or refractory DLBCL masses

  This retrospective study will try drug-eluting bead transarterial chemoembolization (DEB-TACE) to shrink and control large recurrent or refractory DLBCL masses in adults.

  Recruiting Fujian Medical University · Fuzhou, Fujian · NCT07198230

• Comparing metabolic and immune profiles in primary CNS diffuse large B‑cell lymphoma

  This study will test whether people with primary CNS diffuse large B‑cell lymphoma have different metabolic and immune patterns compared with lymphoma patients without CNS involvement and with healthy donors.

  Recruiting Fujian Medical University · Fuzhou, Fujian · NCT07188077

• Combining pomalidomide, rituximab, orelabrutinib and polatuzumab vedotin for elderly diffuse large B‑cell lymphoma

  This tests whether adding polatuzumab vedotin to a pomalidomide, rituximab and orelabrutinib regimen helps patients aged 70 and older with newly diagnosed diffuse large B‑cell lymphoma.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07072208

• Predicting response to first-line DLBCL treatment using ctDNA and PET/CT

  This project will test whether combining a blood ctDNA test with PET/CT scans after two treatment cycles can predict treatment response in people newly diagnosed with DLBCL who are starting standard first-line therapy.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07070648

• DZD8586 combined with immunochemotherapy for diffuse large B‑cell lymphoma

  This trial tests whether adding DZD8586 to standard immunochemotherapy helps people with diffuse large B‑cell lymphoma respond better and what side effects occur.

  Recruiting at 12 sites Phase 1/2 Dizal Pharmaceuticals · Beijing and 12 other locations · NCT07059650

• Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

  A group of elderly patients with newly diagnosed diffuse large B-cell lymphoma will try a lighter chemotherapy approach using three targeted drugs to see if it works and is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07012980

• Pola‑R‑GemOx chemotherapy for relapsed/refractory DLBCL in patients who cannot have an autologous transplant

  This trial will test whether adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin helps people with relapsed or refractory DLBCL who are not eligible for autologous stem‑cell transplant.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07001540

• Combining Loncastuximab and Roflumilast with R-CHOP for High-Risk Diffuse Large B-cell Lymphoma

  This study is testing a new treatment plan that combines loncastuximab and roflumilast with standard chemotherapy to see if it helps people with high-risk diffuse large B-cell lymphoma do better.

  Recruiting at 2 sites Phase 1 The University of Texas Health Science Center at San Antonio · San Antonio, Texas and 1 other locations · NCT06977711

• Treatment with Loncastuximab Tesirine for Lymphoma After CAR-T Therapy Failure

  This study is testing if a new treatment called Loncastuximab Tesirine can help people with lymphoma who didn't get better after CAR-T therapy.

  Recruiting at 7 sites Phase 2 Istituto Clinico Humanitas · Alessandria, ALESSANDRIA and 6 other locations · NCT06918912

• Comparing once vs. twice daily radiation therapy for lymphoma treatment

  This study is testing whether giving radiation therapy once or twice a day can help people with relapsed lymphoma feel better and respond to treatment.

  Recruiting Yale University · New Haven, Connecticut · NCT06898905

• Nemtabrutinib plus pembrolizumab for Richter transformation (DLBCL subtype)

  This phase II trial tests whether combining nemtabrutinib and pembrolizumab can shrink tumors and help people whose chronic lymphocytic leukemia has transformed into diffuse large B‑cell lymphoma (Richter transformation).

  Recruiting Phase 2 Roswell Park Cancer Institute · Buffalo, New York · NCT06863402

• Zanubrutinib with R-CHOP for DLBCL that has MYD88, CD79B, NOTCH1 changes, or is CD5+

  This study will try adding zanubrutinib to standard R-CHOP chemotherapy for adults with DLBCL who have an MYD88 L265P, CD79B, or NOTCH1 truncation mutation, or who are CD5+ by IHC.

  Recruiting Phase 2 Virginia Commonwealth University · Richmond, Virginia · NCT06846463

• Assessing Epcoritamab for Adult Patients with Advanced Lymphoma

  This study is testing if a new skin injection called epcoritamab can help adults with advanced lymphoma feel better and improve their health.

  Recruiting at 73 sites AbbVie · Ciudad Autonoma de Buenos Aire, Buenos Aires and 72 other locations · NCT06830759

• C402 CD19 CAR treatment for relapsed or refractory large B‑cell lymphoma

  We will try an autologous CD19-directed CAR‑T therapy (C402) in adults with relapsed or refractory CD19‑positive large B‑cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Shanghai Exuma Biotechnology Ltd. · Tianjin · NCT06830031

• Treatment for Diffuse Large B Cell Lymphoma using TQB2825 Injection and Immunochemotherapy

  This study is testing a new injection called TQB2825 combined with standard treatments to see if it helps people with untreated or returning diffuse large B-cell lymphoma feel better and live longer.

  Recruiting at 4 sites Phase 1/2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Bengbu, Anhui and 24 other locations · NCT06829771

• Polatuzumab plus R‑CHP with a genotype‑guided targeted drug for untreated DLBCL

  This test will see if adding a genotype‑guided targeted drug to polatuzumab plus R‑CHP helps adults in China with untreated diffuse large B‑cell lymphoma who show limited early ctDNA response.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06803693

• Evaluating vaccine responses in patients with multiple myeloma and non-Hodgkin lymphoma after CAR-T treatment

  This study tests how well vaccines work in people with multiple myeloma and non-Hodgkin lymphoma after they have received CAR-T treatment.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT06784167

• Treatment for relapsed or refractory diffuse large B-cell lymphoma using IOMAB-ACT and CAR-T cell therapy

  This study is testing a new treatment combining a special radioactive drug and CAR-T cell therapy to see if it helps people with relapsed or hard-to-treat diffuse large B-cell lymphoma.

  Recruiting Phase 1/2 University of Texas Southwestern Medical Center · Dallas, Texas · NCT06768905

• Treatment for elderly patients with difficult-to-treat lymphoma

  This study is testing a new treatment for older patients with hard-to-treat lymphoma to see if it can help them go into remission when standard chemotherapy isn't an option.

  Recruiting Phase 2 First Affiliated Hospital of Ningbo University · Ningbo, Zhejiang · NCT06764017

• Comparing R-CMOP and R-CHOP for treating diffuse large B-cell lymphoma

  This study is testing which treatment, R-CMOP or R-CHOP, works better and is safer for adults with low-risk and medium-risk diffuse large B-cell lymphoma.

  Recruiting at 2 sites Phase 1/2 Sun Yat-sen University · Fuzhou, Fujian and 9 other locations · NCT06760039

• Treatment for elderly patients with DLBCL who can't tolerate chemotherapy

  This study is testing a new combination treatment for older patients with diffuse large B-cell lymphoma who can't handle traditional chemotherapy to see if it can help them.

  Recruiting Phase 2 First Affiliated Hospital of Ningbo University · Ningbo, Zhejiang · NCT06758037

• Using PET imaging to predict immunotherapy success in lymphoma patients

  This study is testing if PET scans can help predict how well immunotherapy works for patients with diffuse large B-cell lymphoma.

  Recruiting Ruijin Hospital · Shanghai · NCT06755775

• Testing blood for cancer DNA in patients with B-cell lymphoma

  This study is testing if a blood test for cancer DNA can help identify patients with B-cell lymphoma who are at risk of having their cancer come back in the brain or spinal cord, even when other tests show no signs of it.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06736613

• Evaluating a new treatment combination for untreated diffuse large B-cell lymphoma

  This study is testing a new treatment that combines zilovertamab vedotin with standard chemotherapy to see if it helps people with untreated diffuse large B-cell lymphoma live longer without their cancer getting worse.

  Recruiting at 264 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 287 other locations · NCT06717347

• Optimizing therapy for newly diagnosed diffuse large B-cell lymphoma using ctDNA

  This study is testing if measuring tumor DNA in the blood during treatment can help people with newly diagnosed diffuse large B-cell lymphoma get less chemotherapy if their cancer shows no signs of activity.

  Recruiting Columbia University · New York, New York · NCT06693830

• Preventing CNS relapse in high-risk diffuse large B-cell lymphoma with thiotepa-based treatment

  This study is testing if a special treatment using thiotepa can help newly diagnosed patients with high-risk diffuse large B-cell lymphoma avoid relapsing in the brain after their stem cell transplant.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT06687772

• Polatuzumab with zanubrutinib, rituximab, lenalidomide and prednisone as first-line treatment for diffuse large B-cell lymphoma

  This trial tests whether adding polatuzumab, zanubrutinib, rituximab, lenalidomide, and prednisone is safe and effective as initial treatment for adults with untreated diffuse large B-cell lymphoma.

  Recruiting Phase 2 Navy General Hospital, Beijing · Beijing, Beijing Municipality · NCT06664411

• Combining radiation therapy with lenalidomide and glofitamab for treating relapsed DLBCL

  This study is testing a new treatment combining radiation therapy with lenalidomide and glofitamab to see if it helps people with relapsed diffuse large B-cell lymphoma who haven't responded to other treatments.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06651853

• Evaluating R-CMOP treatment for newly diagnosed diffuse large B-cell lymphoma

  This study is testing a new combination treatment for people with newly diagnosed diffuse large B-cell lymphoma to see if it is safe and effective.

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06594640

• How MYC gene changes relate to the tumor immune environment in diffuse large B‑cell and high‑grade B‑cell lymphoma

  This project will see if MYC gene changes and the tumor's immune environment are linked in adults (18–79) who received curative treatment for diffuse large B‑cell or high‑grade B‑cell lymphoma.

  Recruiting at 14 sites Fondazione Italiana Linfomi - ETS · Alessandria and 19 other locations · NCT06588205

• Preventing CAR-T cell toxicities with emapalumab

  This study is testing if a drug called emapalumab can help prevent side effects in people with large B-cell non-Hodgkin's lymphoma who are receiving another treatment called axicabtagene ciloleucel.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06550141

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Comparing Pola-ZR2 and ZR2 for treating elderly patients with diffuse large B-cell lymphoma

  This study is testing if adding a new drug called polatuzumab vedotin to a standard treatment helps older patients with diffuse large B-cell lymphoma feel better and improve their outcomes.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT06522555

• Using Selinexor with R-CHOP for TP53-mutated DLBCL patients

  This study is testing if adding a new drug called selinexor to the standard treatment for people with untreated TP53-mutated diffuse large B-cell lymphoma can help them get better.

  Recruiting at 2 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT06517511

• Treatment of relapsed or refractory diffuse large B-cell lymphoma with JWCAR201

  This study is testing a new treatment called JWCAR201 to see if it helps adults with hard-to-treat diffuse large B-cell lymphoma feel better.

  Recruiting Phase 1 Fudan University · Shanghai · NCT06517004

• Using zanubrutinib and lenalidomide for maintenance in lymphoma patients

  This study is testing whether the combination of zanubrutinib and lenalidomide can help people with diffuse large B-cell lymphoma stay in remission after chemotherapy.

  Recruiting Phase 2 Navy General Hospital, Beijing · Beijing, Beijing Municipality · NCT06503263

• Testing ZM008 alone and with Pembrolizumab in patients with advanced solid tumors

  This study is testing a new treatment called ZM008, alone and with another drug called Pembrolizumab, to see if it can help patients with advanced solid tumors who have run out of other treatment options.

  Recruiting at 3 sites Phase 1 Zumutor Biologics Inc. · Boston, Massachusetts and 2 other locations · NCT06451497

• Examining the role of inflammation in blood cell deficiencies after CAR-T therapy

  This study is trying to see how inflammation affects blood cell problems in patients with diffuse large B-cell lymphoma after they receive CAR-T therapy.

  Recruiting Instituto de Investigación Biomédica de Salamanca · Salamanca · NCT06439173

• Zilovertamab Vedotin for Pediatric and Young Adult Cancer Patients

  This study is testing a new drug called zilovertamab vedotin to see if it can help kids and young adults with certain types of cancer that haven't responded to other treatments.

  Recruiting at 70 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 70 other locations · NCT06395103

• Evaluating Trogocytosis as a Predictor for CAR-T Cell Therapy Success in Lymphoma

  This study is testing if measuring a process called trogocytosis in immune cells can help predict how well CAR-T cell therapy works for people with lymphoma.

  Recruiting at 2 sites University Hospital, Montpellier · Montpellier and 1 other locations · NCT06352242

• Non-Invasive Detection of Severe Neutropenia in Cancer Patients on High-Risk Therapy

  This study tests PointCheck to see if it can non-invasively flag severe neutropenia in people with certain blood cancers who are receiving higher-risk cancer treatments.

  Recruiting at 6 sites Leuko Labs, Inc. · Honolulu, Hawaii and 5 other locations · NCT06323447

• Treatment of untreated high grade B cell lymphoma with mosunetuzumab and chemotherapy

  This study is testing if a new treatment combining mosunetuzumab and chemotherapy can help people with untreated high grade B cell lymphoma feel better and achieve a complete response.

  Recruiting Phase 1/2 OHSU Knight Cancer Institute · Portland, Oregon · NCT06249191

• Treatment for patients with aggressive non-Hodgkin's lymphoma

  This study is testing a new combination treatment for people with aggressive non-Hodgkin's lymphoma to see if it helps them feel better and improve their health.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06244368

• Using CAR-T cells to treat relapsed CD19+ cancers

  This study is testing if a new type of immune cell treatment can help people with certain cancers that have come back or didn't respond to other treatments.

  Recruiting Phase 1 University of Utah · Salt Lake City, Utah · NCT06227026

• Seeing CXCR4 in lymphoma and leukemia with a new PET tracer

  This study tests a new PET tracer called 18F-BL40 to see if it can image CXCR4-expressing cancers and compares it with the standard 18F-FDG in adults with various blood cancers.

  Recruiting British Columbia Cancer Agency · Vancouver, British Columbia · NCT06224309

• CAR T Cell Therapy for Resistant B-cell Cancers

  This study is testing a new CAR T cell therapy to see if it can safely help people with tough-to-treat B-cell cancers like leukemia and lymphoma.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06213636

• CLIC-2201 treatment for relapsed B cell cancers

  This study is testing a new CAR-T cell therapy called CLIC-2201 to see if it can help people with relapsed B cell cancers feel better and improve their treatment outcomes.

  Recruiting at 7 sites Phase 1 British Columbia Cancer Agency · Calgary, Alberta and 6 other locations · NCT06208735

• Treatment for elderly patients with newly diagnosed diffuse large B cell lymphoma

  This study is testing a new combination treatment for older patients with newly diagnosed diffuse large B cell lymphoma to see if it helps them respond better to therapy.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06176729

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• Using engineered CAR-T cells to treat relapsed diffuse large B-cell lymphoma

  This study is testing a new type of CAR-T cell treatment to see if it can help adults with relapsed diffuse large B-cell lymphoma who haven't responded to other therapies.

  Recruiting Early Phase 1 Zhejiang University · Hangzhou, Zhejiang · NCT06120166

• Bispecific CAR-T cell therapy for relapsed B-cell cancers

  This study is testing a new type of CAR-T cell therapy that targets two cancer markers to see if it helps people with relapsed B-cell cancers feel better and have better outcomes.

  Recruiting Phase 2 Beijing Tongren Hospital · Beijing, Beijing Municipality · NCT06081478

• Using CD79b-19 CAR T cells to treat Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified immune cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT06026319

• Testing ONM-501 alone and with Cemiplimab for advanced solid tumors and lymphomas

  This study is testing a new treatment called ONM-501, both alone and with another drug called cemiplimab, to see if it can help people with advanced solid tumors and lymphomas who have run out of other treatment options.

  Recruiting at 5 sites Phase 1 OncoNano Medicine, Inc. · Los Angeles, California and 15 other locations · NCT06022029

• Zanubrutinib combined with R-CHOP for treating newly diagnosed DLBCL with p53 expression

  This study is testing if a new combination of zanubrutinib and R-CHOP can help people with newly diagnosed diffuse large B-cell lymphoma who have high levels of p53 protein.

  Recruiting Phase 2 Huazhong University of Science and Technology · Wuhan, Hubei · NCT06005870

• Using LV20.19 CAR T-Cells with Pirtobrutinib for B-cell Malignancies

  This study is testing a new treatment combining LV20.19 CAR T-cells with pirtobrutinib to see if it helps adults with tough-to-treat B-cell cancers feel better.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT05990465

• Treatment for elderly patients with untreated diffuse large B-cell lymphoma

  This study is testing a new treatment combining acalabrutinib and rituximab for older or frail patients with untreated diffuse large B-cell lymphoma to see if it works better than standard chemotherapy.

  Recruiting at 46 sites Phase 2 AstraZeneca · Berkeley, California and 56 other locations · NCT05952024

• Combining stem cell collection with CAR T-cell therapy for blood cancers

  This study is testing if collecting stem cells from patients with blood cancers can safely be combined with CAR T-cell therapy to improve treatment outcomes.

  Recruiting Phase 1 Cedars-Sinai Medical Center · Los Angeles, California · NCT05887167

• Evaluating autologous stem cell transplant for high-risk diffuse large B-cell lymphoma

  This study is testing if using a stem cell transplant after standard chemotherapy can help people with high-risk diffuse large B-cell lymphoma feel better and stay healthy longer.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT05831865

• Combining Acalabrutinib with R-miniCHOP for older adults with untreated diffuse large B-cell lymphoma

  This study tests if adding Acalabrutinib to the usual treatment for older adults with untreated diffuse large B-cell lymphoma can help them live longer without their cancer getting worse.

  Recruiting at 9 sites Phase 3 Universität des Saarlandes · Homburg, Saarland and 16 other locations · NCT05820841

• Using itacitinib to improve CAR T cell therapy outcomes in lymphoma patients

  This study is testing if taking itacitinib before and after CAR T cell therapy can help improve outcomes for lymphoma patients with high inflammation levels.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT05757219

• Treatment for relapsed or refractory diffuse large B-cell lymphoma using CAR-T cells and anti-PD1 therapy

  This study is testing a new treatment combining CAR-T cells and an immune therapy for people with relapsed or hard-to-treat diffuse large B-cell lymphoma to see if it helps them.

  Recruiting at 2 sites Phase 1 Ningbo No. 1 Hospital · Hangzhou, Zhejiang and 1 other locations · NCT05659628

• Testing new drug treatments after CAR T-cell therapy for relapsed or refractory lymphoma

  This study is testing if two new drugs can help people with lymphoma who haven't responded to previous CAR T-cell therapy feel better and live longer.

  Recruiting at 89 sites Phase 2 SWOG Cancer Research Network · Tucson, Arizona and 94 other locations · NCT05633615

• Evaluating the effectiveness and safety of tisagenlecleucel therapy in Brazilian patients with B-cell malignancies

  This study is testing how well and safely a treatment called tisagenlecleucel works for Brazilian patients with certain types of blood cancers, including lymphoma and leukemia, over a long follow-up period.

  Recruiting at 7 sites Novartis · Minas Gerais, Belo Horizonte and 6 other locations · NCT05541341

• Treatment protocol for B-cell mature non-Hodgkin's lymphoma in children and adolescents

  This study is testing different treatment plans for children and teenagers with B-cell non-Hodgkin's lymphoma to see who needs stronger therapy and who can safely have gentler options.

  Recruiting Phase 4 Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Moscow, RF · NCT05518383

• Ultra-fraction radiotherapy before CAR-T therapy for relapsed DLBCL

  This study is testing if a special type of radiation treatment before CAR-T therapy can help people with hard-to-treat diffuse large B cell lymphoma feel better and have better results.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT05514327

• Using genetically modified T-cells and a vaccine to treat certain types of B-cell lymphoma after stem cell transplantation

  This study is testing a new treatment using specially modified immune cells and a vaccine to see if it can help people with certain types of B-cell lymphoma after they've had a stem cell transplant.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT05432635

• Long-term follow-up of gene-edited immune cell therapy for lymphoma

  This study is checking how safe and effective a gene-edited immune cell therapy is for people with lymphoma who received the treatment in the past.

  Recruiting at 5 sites Pell Bio-Med Technology Co., Ltd. · Kaohsiung, Taiwan and 4 other locations · NCT05377307

• IKS03 treatment for advanced B cell non-Hodgkin lymphomas

  This study is testing a new treatment called IKS03 for people with advanced B cell non-Hodgkin lymphoma to see how safe and effective it is.

  Recruiting at 12 sites Phase 1 Iksuda Therapeutics Ltd. · Baltimore, Maryland and 12 other locations · NCT05365659

• Local production of CAR T-cells for treating B-Cell cancers

  This study is testing whether making CAR T-cells locally can help patients with B-Cell lymphoma and leukemia have a safe and effective treatment.

  Recruiting Phase 2 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT05281809

• Combining R-CDOP and intrathecal methotrexate for high-risk DLBCL patients

  This study is testing a new combination of chemotherapy and a specific type of treatment for high-risk patients with untreated diffuse large B-cell lymphoma to see if it helps prevent serious complications in the brain.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT05257018

• Using acalabrutinib to prevent relapse in patients with large B-cell lymphoma

  This study is testing if the drug acalabrutinib can help prevent cancer from coming back in patients with large B-cell lymphoma who are at high risk after treatment.

  Recruiting at 2 sites Phase 1/2 Jonsson Comprehensive Cancer Center · Los Angeles, California and 2 other locations · NCT05256641

• Assessing ctDNA for monitoring lymphoma patients receiving CAR therapy

  This study is testing if measuring tumor DNA in the blood can help doctors keep track of lymphoma patients receiving CAR therapy and see if their cancer is coming back sooner than traditional scans.

  Recruiting Adaptive Biotechnologies · Palo Alto, California · NCT05255354

• Treatment for relapsed or refractory diffuse large B-cell lymphoma using zilovertamab vedotin

  This study is testing a new treatment called zilovertamab vedotin for adults with relapsed or refractory diffuse large B-cell lymphoma to see if it works better than standard care.

  Recruiting at 43 sites Phase 2/3 Merck Sharp & Dohme LLC · Glendale, Arizona and 134 other locations · NCT05139017

• Treatment for newly diagnosed high tumor burden non-Hodgkin's lymphoma

  This study is testing a new treatment combination for people with newly diagnosed high tumor burden non-Hodgkin's lymphoma to see if it helps them feel better and stay safe.

  Recruiting The First Hospital of Jilin University · Changchun, Jilin · NCT05040555

• Comparing two treatment regimens for low-risk diffuse large B cell lymphoma

  This study is testing two different treatment plans for people with low-risk diffuse large B cell lymphoma to see which one works better and causes fewer side effects.

  Recruiting Phase 3 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT05018520

• Exploring BGB-16673 for treating B-cell malignancies

  This study is testing a new drug called BGB-16673 to see if it can safely help people with certain types of B-cell cancers, like Marginal Zone Lymphoma and Follicular Lymphoma, who haven't had success with other treatments.

  Recruiting at 104 sites Phase 1/2 BeOne Medicines · Birmingham, Alabama and 113 other locations · NCT05006716

• MB-CART2019.1 versus standard chemotherapy for relapsed/refractory diffuse large B‑cell lymphoma

  This study will test whether MB‑CART2019.1, a CD20/CD19 CAR‑T cell therapy, works better than standard chemotherapy for people with relapsed or refractory diffuse large B‑cell lymphoma who are not eligible for high‑dose chemotherapy and autologous stem cell transplant.

  Recruiting at 39 sites Phase 2 Miltenyi Biomedicine GmbH · Graz and 50 other locations · NCT04844866

• Oral treatment with LP-168 for patients with certain blood cancers

  This study is testing an oral treatment called LP-168 to see if it can help adults with certain types of blood cancers that have come back or didn't respond to other treatments.

  Recruiting at 4 sites Phase 1 Newave Pharmaceutical Inc · Durham, North Carolina and 3 other locations · NCT04775745

• Impact of physical activity on survival in patients with diffuse large B cell lymphoma

  This study tests if a special exercise program can help older patients with diffuse large B cell lymphoma live longer and have fewer relapses while they are getting their first treatment.

  Recruiting at 3 sites Phase 3 Weprom · Besançon and 4 other locations · NCT04670029

• Using modified T cells to treat relapsed or refractory Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified T cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT04545762

• KRT-232 plus acalabrutinib in relapsed/refractory DLBCL or CLL

  This trial tests a new MDM2 inhibitor (KRT-232) together with acalabrutinib to see if the combination helps adults with relapsed or refractory DLBCL or CLL.

  Recruiting at 45 sites Phase 1/2 Kartos Therapeutics, Inc. · Goshen, Indiana and 44 other locations · NCT04502394

• Using stem cell transplant and Polatuzumab Vedotin for treating B-cell lymphomas

  This study is testing if a stem cell transplant followed by a new drug called Polatuzumab Vedotin can help people with different types of B-cell lymphomas feel better.

  Recruiting Phase 1/2 New York Medical College · Valhalla, New York · NCT04491370

• Treatment with Prednisone and Vitamin D for Elderly Patients with Lymphoma

  This study is testing if adding Vitamin D to the usual treatment with prednisone helps older patients with lymphoma do better during their cancer treatment.

  Recruiting at 21 sites Phase 3 Fondazione Italiana Linfomi - ETS · Brescia, BS and 48 other locations · NCT04442412

• Comparing two treatments for elderly patients with diffuse large B-cell lymphoma

  This study is testing whether a new treatment for elderly patients with diffuse large B-cell lymphoma works better than the standard treatment.

  Recruiting at 52 sites Phase 3 Nordic Lymphoma Group · Albury and 68 other locations · NCT04332822

• Identifying biomarkers in Diffuse Large B-cell Lymphoma

  This study is trying to find new markers in tissue samples that can help predict how well patients with Diffuse Large B-cell Lymphoma will do over time.

  Recruiting at 4 sites Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Meldola, FC and 3 other locations · NCT04300101

• CAR-T cell therapy for patients with relapsed B cell cancers

  This study is testing a new CAR-T cell therapy for adults with relapsed B cell cancers to see how well it works and if different manufacturing methods make a difference in treatment outcomes.

  Recruiting Phase 1/2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT04186520

• Tulmimetostat treatment for advanced solid tumors and lymphomas

  This study is testing a new treatment called Tulmimetostat to see if it can help people with advanced solid tumors and lymphomas feel better and fight their cancer.

  Recruiting at 43 sites Phase 1/2 Novartis · Tampa, Florida and 79 other locations · NCT04104776

• Evaluating safety of tisagenlecleucel that doesn't meet specifications

  This study is testing a special treatment called tisagenlecleucel to see if it is safe and works for kids and young adults with a type of leukemia and adults with a type of lymphoma, even if the treatment doesn't meet standard quality checks.

  Recruiting at 49 sites Phase 3 Novartis · Hamilton, Ontario and 54 other locations · NCT04094311

• Combining acalabrutinib with standard chemotherapy for untreated aggressive B-cell lymphoma

  This study is testing if adding a new drug called acalabrutinib to standard chemotherapy can help people with untreated aggressive B-cell lymphoma get better results.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT04002947

• Treatment for relapsed or refractory CD19+ lymphoid diseases using engineered T cells

  This study is testing a new treatment using specially modified immune cells to help adults and children with certain types of blood cancers that haven't responded to other therapies.

  Recruiting at 2 sites Phase 1/2 University Hospital Heidelberg · Heidelberg and 1 other locations · NCT03676504

• Evaluating immune responses to influenza vaccination in lymphoma patients

  This study is testing how well the flu vaccine works for people with lymphoma by checking their immune responses after getting vaccinated.

  Recruiting at 2 sites Emory University · Atlanta, Georgia and 1 other locations · NCT03501576

• Long-term follow-up of patients receiving CAR-T cell therapy

  This study is tracking patients who have received CAR-T cell therapy for up to 15 years to see how well the treatment works over time and if there are any long-term health issues.

  Recruiting Medical College of Wisconsin · Milwaukee, Wisconsin · NCT03375619

• Combination treatment for relapsed B-cell lymphoma

  This study is testing a new combination of five drugs to see if it can help people with relapsed or hard-to-treat B-cell lymphoma feel better.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03223610

• Using obinutuzumab with chemotherapy for relapsed CD20+ Non-Hodgkin Lymphoma in young patients

  This study is testing if a new drug called obinutuzumab, alone or with chemotherapy, can help young patients with relapsed CD20 positive Non-Hodgkin Lymphoma feel better and improve their treatment results.

  Recruiting Phase 2 New York Medical College · Valhalla, New York · NCT02393157

Related topics

Quick answers

How many Diffuse Large B Cell Lymphoma clinical trials are recruiting right now?

105, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 52 countries. The most sites are in United States (46 trials), China (41 trials), Italy (14 trials), Spain (10 trials), Australia (9 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 29, Phase 1: 19, Phase 1/2: 17, Phase 3: 9. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →